Current knowledge and future research directions in treatment-related second primary malignancies

European Journal of Cancer, Supplement

Volumn 12, Issue 1, 2014, Pages 5-17

  Morton, Lindsay M ^a   Swerdlow, Anthony J ^b   Schaapveld, Michael ^c   Ramadan, Safaa ^d   Hodgson, David C ^e   Radford, John ^f   van Leeuwen, Flora E ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d EORTC DATA CENTER   (Belgium)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Multiple primary malignancies or multiple primary neoplasms; Radiotherapy; Treatment induced

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SURVIVOR; CARCINOGENESIS; CLINICAL EFFECTIVENESS; DRUG INDUCED CANCER; ENVIRONMENTAL FACTOR; EXERCISE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LIFESTYLE; MAMMOGRAPHY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION DOSE; RESEARCH PRIORITY; RISK FACTOR; RISK REDUCTION; SECOND CANCER; SMOKING; SMOKING CESSATION; SYSTEMIC THERAPY; TREATMENT PLANNING; WEIGHT CONTROL; WEIGHT REDUCTION;

EID: 84904739193     PISSN: 13596349     EISSN: 18781217     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2014.05.001     Document Type: Article

References (129)

1. Netherlands Cancer Registry. Personal communication Otto Visser.; 2013. http://www.iknl.nl.
2. Morton L., Onel K., Curtis R.E., Hungate E., Armstrong G.T. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol 2014, [in press].
3. Aleman B.M.P., van den Belt-Dusebout A.W., Klokman W.J., van't Veer M.B., Bartelink H., van Leeuwen F.E. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003, 21(18):3431-3439.
4. Ng A.K., Bernardo M.P., Weller E., Backstrand K.H., Silver B., Marcus K.C., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002, 20(8):2101-2108.
5. Boice J.D., Storm H.H., Curtis R.E., Jensen O.M., Kleinerman R.A., Jensen H.S., et al. Introduction to the study of multiple primary cancers. Natl Cancer Inst Monogr 1985, 68:3-9.
6. Hodgson D., van Leeuwen F.E. Second malignancy risk after treatment of Hodgkin lymphoma. Hematologic malignancies: Hodgkin lymphoma a comprehensive update on diagnostics and clinics 2011, 305-331. Springer Verlag, Berlin Heidelberg. Second ed. A.H.S. Engert (Ed.).
7. Travis L.B., Wahnefried W.D., Allan J.M., Wood M.E., Ng A.K. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013, 10(5):289-301.
8. United Nations Scientific Committee on the Effects of Atomic Radiation UNSCEAR 2006. Report: effect of ionizing radiation, Volume 1 - Report to the General Assembly, with Scientific Annexes A and B. Vienna; 2008.
9. IARC (International Agency for Research on Cancer). Monographs on the evaluation of carcinogenic risks to humans. Vol. 75. Ionizing radiation, part 1: X- and gamma-radiation, and neutrons. Lyon, France; 2000.
10. IARC (International Agency for Research on Cancer) Some antiviral and antineoplastic drugs, and other pharmaceutical agents. IARC Monogr Eval Carcinog Risk Chem Hum 2000, 76:177.
11. Committee to assess health risks from exposure to low levels of ionizing radiation: health risks from exposure to low levels of ionizing radiation, BEIR VII< Phase 2. Washington, DC; 2006.
12. Morton L.M., Dores G.M., Curtis R.E., Lynch C.F., Stovall M., Hall P., et al. Stomach cancer risk after treatment for Hodgkin lymphoma. J Clin Oncol 2013, 31(27):3369-3377.
13. Travis L.B., Hill D.A., Dores G.M., Gospodarowicz M., van Leeuwen F.E., Holowaty E., et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin's disease. JAMA 2003, 290(4):465-475.
14. Gilbert E.S., Stovall M., Gospodarowicz M., van Leeuwen F.E., Andersson M., Glimelius B., et al. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003, 159(2):161-173.
15. Neglia J.P., Robison L.L., Stovall M., Liu Y., Packer R.J., Hammond S., et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006, 98(21):1528-1537.
16. Henderson T.O., Rajaraman P., Stovall M., Constine L.S., Olive A., Smith S.A., et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 2012, 84(1):224-230.
17. Bhatti P.V.L., Ronckers C.M., Sigurdson A.J., Stovall M., Smith S.A., Weathers R., et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the Childhood Cancer Survivor Study. Radiat Res 2010, 174(6):741-752.
18. Boice J.D., Blettner M., Kleinerman R.A., Stovall M., Moloney W.C., Engholm G., et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 1987, 79:1295-1311.
19. Berrington de Gonzalez A., Gilbert E., Curtis R., Inskip P., Kleinerman R., Morton L., et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys 2013, 86(2):224-233.
20. Hodgson D.C., Gilbert E.S., Dores G.M., Schonfeld S.J., Lynch C.F., Storm H., et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007, 25(12):1489-1497.
21. Travis L.B., Fossa S.D., Schonfeld S.J., McMaster M.L., Lynch C.F., Storm H., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005, 97(18):1354-1365.
22. Yoon M., Ahn S.H., Kim J., Shin D.H., Park S.Y., Lee S.B., et al. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy. Int J Radiat Oncol Biol Phys 2010, 77(5):1477-1485.
23. Murray L.H.A., Hoskin P., Siebert F.A., Venselaar J. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol 2014, 110(2):213-228.
24. Hodgson D.C. Late effects in the era of modern therapy for Hodgkin lymphoma. ASH Educ Prog Book 2011, 2011(1):323-329.
25. De Bruin M.L., Sparidans J., van't Veer M.B., Noordijk E., Louwman M.W., Zijlstra J.M., et al. Breast cancer risk in female survivors of Hodgkin's lymphoma; lower risk after smaller radiation volumes. J Clin Oncol 2009, 27(26):4229-4231.
26. Vardiman J.W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010, 184(1-2):16-20.
27. Morton L.M., Dores G.M., Tucker M.A., Kim C.J., Onel K., Gilbert E.S., et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013, 121(15):2996-3004.
28. Leone G., Fianchi L., Pagano L., Voso M.T. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact 2010, 184(1-2):39-45.
29. Xu Y., Wang H., Zhou S., Yu M., Wang X., Fu K., et al. Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2013, 54(7):1396-1404.
30. Diamandidou E., Buzdar A.U., Smith T.L., Frye D., Witjaksono M., Hortobagyi G.N. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 1996, 14(10):2722-2730.
31. Travis L.B., Holowaty E.J., Bergfeldt K., Lynch C.F., Kohler B.A., Wiklund T., et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999, 340(5):351-357.
32. Travis L.B., Andersson M., Gospodarowicz M., van Leeuwen F.E., Bergfeldt K., Lynch C.F., et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000, 92(14):1165-1171.
33. RamaChandran S., Ariffin H. Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2009, 53(3):488-490.
34. Praga C., Bergh J., Bliss J., Bonneterre J., Cesana B., Coombes R.C., et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005, 23(18):4179-4191.
35. Le Deley M.-C., Suzan F., Cutuli B., Delaloge S., Shamsaldin A., Linassier C., et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007, 25(3):292-300.
36. Smith R.E., Bryant J., DeCillis A., Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003, 21(7):1195-1204.
37. Boshoff C., Begent R.H., Oliver R.T., Rustin G.J., Newlands E.S., Andrews R., et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995, 6:35-40.
38. Curtis R.E., Boice J.D., Stovall M., Bernstein L., Greenberg R.S., Flannery J.T., et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer [see comments]. N Engl J Med 1992, 326:1745-1751.
39. Döhner H., Estey E., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(3):453-474.
40. Kayser S., Döhner K., Krauter J., Köhne C.H., Horst H.A., Held G., et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011, 117(7):2137-2145.
41. Pendleton M., Lindsey R.H., Felix C.A., Grimwade D., Osheroff N. Topoisomerase II and leukemia. Ann N Y Acad Sci 2014, 1310(1):98-110.
42. Travis L.B., Gospodarowicz M., Curtis R.E., Clarke E.A., Andersson M., Glimelius B., et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002, 94(3):182-192.
43. Swerdlow A.J., Schoemaker M.J., Allerton R., Horwich A., Barber J.A., Cunningham D., et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001, 19(6):1610-1618.
44. André M., Mounier N., Leleu X., Sonet A., Brice P., Henry-Amar M., et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004, 103(4):1222-1228.
45. Mudie N.Y., Swerdlow A.J., Higgins C.D., Smith P., Qiao Z., Hancock B.W., et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British cohort study. J Clin Oncol 2006, 24(10):1568-1574.
46. Swerdlow A.J., Higgins C.D., Smith P., Cunningham D., Hancock B.W., Horwich A., et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011, 29(31):4096-4104.
47. Henderson T.O.O.K., Whitton J., Leisenring W., Neglia J., Meadows A., Crotty C., et al. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Int Med 2012, 156(11):757-766.
48. Tucker M.A., D'Angio G.J., Boice J.D., Strong L.C., Li F.P., Stovall M., et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987, 317:588-593.
49. Veiga L.H.S., Bhatti P., Ronckers C.M., Sigurdson A.J., Stovall M., Smith S.A., et al. Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study. Cancer Epidemiol Biomark Prev 2012, 21(1):92-101.
50. Travis L.B., Curtis R.E., Glimelius B., Holowaty E.J., van Leeuwen F.E., Lynch C.F., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995, 87:524-530.
51. Bermejo J.L., Sundquist J., Hemminki K. Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br J Cancer 2009, 101(7):1091-1099.
52. Nottage K., McFarlane J., Krasin M.J., Li C., Srivastava D., Robison L.L., et al. Secondary colorectal carcinoma after childhood cancer. J Clin Oncol 2012, 30(20):2552-2558.
53. van den Belt-Dusebout A.W., Aleman B.M., Besseling G., de Bruin M.L., Hauptmann M., van't Veer L.J., et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009, 75(5):1420-1429.
54. Mackey J.R., Martin M., Pienkowski T., Rolski J., Guastalla J.-P., Sami A., et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013, 14(1):72-80.
55. Vay A., Kumar S., Seward S., Semaan A., Schiffer C.A., Munkarah A.R., et al. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis. Gynecol Oncol 2011, 123(3):456-460.
56. Jones S., Holmes F.A., O'Shaughnessy J., Blum J.L., Vukelja S.J., McIntyre K.J., et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol 2009, 27(8):1177-1183.
57. Petrelli F., Borgonovo K., Cabiddu M., Lonati V., Barni S. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat 2012, 135(2):335-346.
58. Mamounas E.P., Bryant J., Lembersky B., Fehrenbacher L., Sedlacek S.M., Fisher B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP b-28. J Clin Oncol 2005, 23(16):3686-3696.
59. Lyman G.H., Dale D.C. Long-term outcomes of myeloid growth factor treatment. J Natl Compr Canc Netw 2011, 9(8):945-952.
60. Palumbo A., Bringhen S., Kumar S.K., Lupparelli G., Usmani S., Waage A., et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014, 15(3):333-342.
61. Zhao J., Xu Z., Liu D., Lu Q. Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell Int 2012, 12(1):38.
62. Zhou Y., Tang G., Medeiros L.J., McDonnell T.J., Keating M.J., Wierda W.G., et al. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 2012, 25(2):237-245.
63. Baldo B. Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses. Oncoimmunology 2013, 2(10):e26333.
64. Swerdlow A.J., Jones M.E. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005, 97:375-384.
65. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000, 356(9233):881-887.
66. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) DC, Davies C., Godwin J., Gray R., Clarke M., Cutter D., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet Oncol 2011, 378(9793):771-784.
67. Kaldor J.M., Day N.E., Clarke E.A., van Leeuwen F.E., Henry-Amar M., Fiorentino M.V., et al. Leukemia following Hodgkin's disease [see comments]. N Engl J Med 1990, 322:7-13.
68. Swerdlow A.J., Barber J.A., Hudson G.V., Cunningham D., Gupta R.K., Hancock B.W., et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000, 18(3):498-509.
69. van Leeuwen F.E., Klokman W.J., Stovall M., Dahler E.C., van't Veer M.B., Noordijk E.M., et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95(13):971-980.
70. Inskip P.D., Robison L.L., Stovall M., Smith S.A., Hammond S., Mertens A.C., et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009, 27(24):3901-3907.
71. Swerdlow A.J., Cooke R., Bates A., Cunningham D., Falk S.J., Gilson D., et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a national cohort study. J Clin Oncol 2012, 30(22):2745-2752.
72. Veiga L.H.L.J., Anderson H., de Vathaire F., Tucker M., Bhatti P., Schneider A., et al. A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. Radiat Res 2012, 178(4):365-376.
73. Ng A., Kenney L., Gilbert E., Travis L. Secondary malignancies across the age spectrum. Sem Radiat Oncol 2010, 20(1):67-78.
74. Little M.P., Weiss H.A., Boice J.D., Darby S.C., Day N.E., Muirhead C.R. Risks of leukemia in Japanese atomic bomb survivors, in women treated for cervical cancer, and in patients treated for ankylosing spondylitis. Radiat Res 1999, 152(3):280-292.
75. Cooke R., Jones M.E., Cunningham D., Falk S.J., Gilson D., Hancock B.W., et al. Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. Br J Cancer 2013, 108(11):2399-2406.
76. Morton L.M., Chanock S.J. A step toward slaying the hydra of second cancers. Nat Med 2011, 17(8):924-925.
77. Suri J., Rednam S., Teh B., Butler E., Paulina A. Subsequent malignancies in patients with Li-Fraumeni syndrome treated with radiation therapy. Int J Radiat Oncol Biol Phys 2013, 87(2, supplement):S71-S72.
78. Larson R.A., Wang Y., Banerjee M., Wiemels J., Hartford C., Beau M.M.L., et al. Prevalence of the Inactivating 609C→T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999, 94(2):803-807.
79. Allan J.M., Wild C.P., Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci 2001, 98(20):11592-11597.
80. Worrillow L.J., Smith A.G., Scott K., Andersson M., Ashcroft A.J., Dores G.M., et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008, 45(3):142-146.
81. Worrillow L.J., Travis L.B., Smith A.G., Rollinson S., Smith A.J., Wild C.P., et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003, 9(8):3012-3020.
82. Seedhouse C., Bainton R., Lewis M., Harding A., Russell N., Das-Gupta E. The genotype distribution of the XRCC1gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002, 100(10):3761-3766.
83. Seedhouse C., Faulkner R., Ashraf N., Das-Gupta E., Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004, 10(8):2675-2680.
84. Bhatla D., Gerbing R.B., Alonzo T.A., Mehta P.A., Deal K., Elliott J., et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia 2007, 22(2):265-272.
85. Brooks J.D., Teraoka S.N., Reiner A.S., Satagopan J.M., Bernstein L., Thomas D.C., et al. Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. Hum Mutat 2012, 33(1):158-164.
86. Broeks A., Braaf L.M., Huseinovic A., Nooijen A., Urbanus J., Hogervorst F.B., et al. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res 2007, 9(2):R26.
87. Chung C., Chanock S. Current status of genome-wide association studies in cancer. Hum Genet 2011, 130(1):59-78.
88. Knight J.A., Skol A.D., Shinde A., Hastings D., Walgren R.A., Shao J., et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009, 113(22):5575-5582.
89. Best T., Li D., Skol A.D., Kirchhoff T., Jackson S.A., Yasui Y., et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011, 17(8):941-943.
90. Kerns S.L., Stock R.G., Stone N.N., Blacksburg S.R., Rath L., Vega A., et al. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiother Oncol 2013, 107(3):372-376.
91. Kerns S.L., Stone N., Stock R.G., Rath L., Ostrer H., Rosenstein B.S. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. J Urol 2013, 190(1):102-108.
92. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995, 87(20):1530-1537.
93. Neugut A.I., Murray T., Santos J., Amols H., Hayes M.K., Flannery J.T., et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers [see comments]. Cancer 1994, 73:1615-1620.
94. Kaufman E.L., Jacobson J.S., Hershman D.L., Desai M., Neugut A.I. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008, 26(3):392-398.
95. Prochazka M., Hall P., Gagliardi G., Granath F., Nilsson B.N., Shields P.G., et al. Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol 2005, 23(30):7467-7474.
96. Hill D.A., Gilbert E., Dores G.M., Gospodarowicz M., van Leeuwen F.E., Holowaty E., et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005, 106(10):3358-3365.
97. Kenney L.B., Yasui Y., Inskip P.D., Hammond S., Neglia J.P., Mertens A.C., et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 2004, 141(8):590-597.
98. Ralleigh G., Given-Wilson R. Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin's disease. Clin Radiol 2004, 59(8):647-650.
99. Saslow D., Boetes C., Burke W., Harms S., Leach M.O., Lehman C.D., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75-89.
100. Mulder R.L., Kremer L.C.M., Hudson M.M., Bhatia S., Landier W., Levitt G., et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2013, 14(13):e621-e629.
101. Henderson T., Amsterdam A., Bhatia S., Hudson M., Meadows A., Neglia J., et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010, 152(7):444-455.
102. Howell S.J., Searle C., Goode V., Gardener T., Linton K., Cowan R.A., et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer 2009, 101(4):582-588.
103. Hodgson D.C., Grunfeld E., Gunraj N., Del Giudice L. A population-based study of follow-up care for Hodgkin lymphoma survivors: opportunities to improve surveillance for relapse and late effects. Cancer 2010, 116(14):3417-3425.
104. Yahalom J., Petrek J.A., Biddinger P.W., Kessler S., Dershaw D.D., McCormick B., et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients [see comments]. J Clin Oncol 1992, 10:1674-1681.
105. Diller L., Medeiros Nancarrow C., Shaffer K., Matulonis U., Mauch P., Neuberg D., et al. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol 2002, 20(8):2085-2091.
106. Lee L., Pintilie M., Hodgson D.C., Goss P.E., Crump M. Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma. Ann Oncol 2008, 19(1):62-67.
107. Elkin E.B., Klem M.L., Gonzales A.M., Ishill N.M., Hodgson D., Ng A.K., et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol 2011, 29(18):2466-2473.
108. Wolden S.L., Hancock S.L., Carlson R.W., Goffinet D.R., Jeffrey S.S., Hoppe R.T. Management of breast cancer after Hodgkin's disease. J Clin Oncol 2000, 18(4):765-772.
109. Sung J.S., Malak S.F., Bajaj P., Alis R., Dershaw D.D., Morris E.A. Screening breast MR imaging in women with a history of lobular carcinoma in situ. Radiology 2011, 261(2):414-420.
110. Ng A.K., Garber J.E., Diller L.R., Birdwell R.L., Feng Y., Neuberg D.S., et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of hodgkin lymphoma. J Clin Oncol 2013, 31(18):2282-2288.
111. Hoogendoorn W.E., Hollema H., van Boven H.H., Bergman E., Leeuw-Mantel G., Platteel I., et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat 2008, 112(1):99-108.
112. Jones M., van Leeuwen F., Hoogendoorn W., Mourits M., Hollema H., van Boven H., et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 2012, 14(3):R91.
113. Page V., Gardner A., Karzmark C.J. Physical and dosimetric aspects of the radiotherapy of malignant lymphomas I the mantle field technique. Radiology 1970, 96(3):609-618.
114. Page V., Gardner A., Karzmark C.J. Physical and dosimetric aspects of the radiotherapy of malignant lymphomas II the inverted Y-technique. Radiology 1970, 96(3):619-626.
115. Engert A., Plütschow A., Eich H.T., Lohri A., Dörken B., Borchmann P., et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010, 363(7):640-652.
116. Girinsky T., van der Maazen R., Specht L., Aleman B., Poortmans P., Lievens Y., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79(3):270-277.
117. Hoskin P.J., Díez P., Williams M., Lucraft H., Bayne M. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol 2013, 25(1):49-58.
118. Meyer R.M., Gospodarowicz M.K., Connors J.M., Pearcey R.G., Bezjak A., Wells W.A., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005, 23(21):4634-4642.
119. Meyer R.M., Gospodarowicz M.K., Connors J.M., Pearcey R.G., Wells W.A., Winter J.N., et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012, 366(5):399-408.
120. Radford J., O'Doherty M., Barrington S., Qian W., Patrick P., Coltar S. Results of the 2nd planned interim analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a 'negative' FDG-PET scan after 3 cycles ABVD. ASH Annu Meet Abs 2008, 112(11):369.
121. Scott D.W., Chan F.C., Hong F., Rogic S., Tan K.L., Meissner B., et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 2013, 31(6):692-700.
122. Palomares M. ; 2013. http://www.cancer.gov/clinicaltrials/search/view?cdrid=687084%26version=HealthProfessional.
123. Taylor A.J., Winter D.L., Stiller C.A., Murphy M., Hawkins M.M. Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain: a population-based study. Int J Cancer 2007, 120(2):384-391.
124. Moskowitz C., Chou J.F., Wolden S.L., Bernstein J.L., Malhotra J., Novetsky Friedman D., et al. New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: a report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study. J Clin Oncol 2012, 30(18, Supplement). ASCO Annual Meeting Abstracts CRA9513.
125. Hartmann L.C., Schaid D.J., Woods J.E., Crotty T.P., Myers J.L., Arnold P.G., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340(2):77-84.
126. Ames B., Gold L.S., Willett W.C. The causes and prevention of cancer. Proc Natl Acad Sci USA 1995, 92(12):5258.
127. Hodgson D.C., Koh E.-S., Tran T.H., Heydarian M., Tsang R., Pintilie M., et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007, 110(11):2576-2586.
128. Ng A., Brock K.K., Sharpe M.B., Moseley J.L., Craig T., Hodgson D.C. Individualized 3D reconstruction of normal tissue dose for patients with long-term follow-up: a step toward understanding dose risk for late toxicity. Int J Radiat Oncol Biol Phys 2012, 84(4):e557-e563.
129. Oeffinger K.C., van Leeuwen F.E., Hodgson D.C. Methods to assess adverse health-related outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev 2011, 20(10):2022-2034.